DrugPatentWatch Database Preview

Details for Patent: 6,335,369

« Back to Dashboard

Which drugs does patent 6,335,369 protect, and when does it expire?

Patent 6,335,369 protects CARNITOR and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 6,335,369

Title:	Treating chronic uremic patients undergoing periodical dialysis
Abstract:	Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Inventor(s):	Cavazza; Claudio (Rome, IT)
Assignee:	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:	09/761,639
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,335,369
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 6,335,369

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	AP	RX	Yes	Yes						USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

International Family Members for US Patent 6,335,369

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3050201
Canada	2381187
European Patent Office	1257266
World Intellectual Property Organization (WIPO)	0152836